Clinical Trials Browser

Recruiting × eltrombopag × Myeloid × Clear all

NCT06630221 2025-07-03

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic